Brief: Cstone Pharmaceuticals Announces NMPA Approval For Localized Manufacturing Of Gavreto (Pralsetinib) In China
10/07/2025 02:25
July 10 (Reuters) - CStone Pharmaceuticals 2616.HK: NMPA APPROVAL FOR LOCALIZED MANUFACTURING OF GAVRETO (PRALSETINIB) IN CHINA Further company coverage: 2616.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026